Acadia Pharmaceuticals (ACAD) EBIAT: 2009-2025
Historic EBIAT for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $71.8 million.
- Acadia Pharmaceuticals' EBIAT rose 119.07% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 103.24%. This contributed to the annual value of $226.5 million for FY2024, which is 469.50% up from last year.
- Acadia Pharmaceuticals' EBIAT amounted to $71.8 million in Q3 2025, which was up 169.18% from $26.7 million recorded in Q2 2025.
- Over the past 5 years, Acadia Pharmaceuticals' EBIAT peaked at $143.7 million during Q4 2024, and registered a low of -$113.1 million during Q1 2022.
- Its 3-year average for EBIAT is $25.7 million, with a median of $26.7 million in 2025.
- In the last 5 years, Acadia Pharmaceuticals' EBIAT plummeted by 139.77% in 2023 and then spiked by 2,897.22% in 2024.
- Over the past 5 years, Acadia Pharmaceuticals' EBIAT (Quarterly) stood at -$43.1 million in 2021, then climbed by 3.18% to -$41.7 million in 2022, then soared by 209.76% to $45.8 million in 2023, then spiked by 213.87% to $143.7 million in 2024, then soared by 119.07% to $71.8 million in 2025.
- Its last three reported values are $71.8 million in Q3 2025, $26.7 million for Q2 2025, and $19.0 million during Q1 2025.